1. A genome‐wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain. (18th March 2015) Authors: Meng, W.; Deshmukh, H.A.; van Zuydam, N.R.; Liu, Y.; Donnelly, L.A.; Zhou, K.; Morris, A.D.; Colhoun, H.M.; Palmer, C.N.A.; Smith, B.H. Journal: European journal of pain Issue: Volume 19:Number 3(2015) Page Start: 392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A genome‐wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain. (26th June 2014) Authors: Meng, W.; Deshmukh, H.A.; van Zuydam, N.R.; Liu, Y.; Donnelly, L.A.; Zhou, K.; Wellcome Trust Case Control Consortium 2 (WTCCC2); Surrogate Markers for Micro‐ and Macro‐Vascular Hard Endpoints for Innovative Diabetes Tools (SUMMIT) Study Group; Morris, A.D.; Colhoun, H.M.; Palmer, C.N.A.; Smith, ... Journal: European journal of pain Issue: Volume 19:Number 3(2015) Page Start: 392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A genome‐wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain. (March 2015) Authors: Meng, W.; Deshmukh, H.A.; van Zuydam, N.R.; Liu, Y.; Donnelly, L.A.; Zhou, K.; Morris, A.D.; Colhoun, H.M.; Palmer, C.N.A.; Smith, B.H. Journal: European journal of pain Issue: Volume 19:Number 3(2015) Page Start: 392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A genome‐wide association study suggests that MAPK14 is associated with diabetic foot ulcers. (1st December 2017) Authors: Meng, W.; Veluchamy, A.; Hébert, H.L.; Campbell, A.; Colhoun, H.M.; Palmer, C.N.A. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A genome‐wide association study suggests that MAPK14 is associated with diabetic foot ulcers3. (27th November 2017) Authors: Meng, W.; Veluchamy, A.; Hébert, H.L.; Campbell, A.; Colhoun, H.M.; Palmer, C.N.A. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Lipoprotein(A) Predicts Cardiovascular Events In Statin Outcome Trials: Pooled Analysis Of Seven Randomised Controlled Trials. (August 2019) Authors: Willeit, P.; Ridker, P.; Nestel, P.J.; Simes, J.; Tonkin, A.M.; Pedersen, T.R.; Schwartz, G.G.; Olsson, A.G.; Colhoun, H.M.; Kronenberg, F.; Drechsler, C.; Wanner, C.; Mora, S.; Lesogor, A.; Tsimikas, S. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PARAMETERS DERIVED FROM RESERVOIR PRESSURE ANALYSIS INDEPENDENTLY PREDICT CARDIOVASCULAR EVENTS IN A MULTI-CENTRE STUDY OF INDIVIDUALS WITH TYPE 2 DIABETES. (June 2018) Authors: Aizawa, K.; Casanova, F.; Mawson, D.M.; Gooding, K.M.; Strain, W.D.; Gates, P.E.; Östling, G.; Nilsson, J.; Khan, F.; Colhoun, H.M.; Palombo, C.; Parker, K.H.; Shore, A.C.; Hughes, A.D. Journal: Journal of hypertension Issue: Volume 36(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. (September 2016) Authors: Robinson, J.G.; Farnier, M.; Kastelein, J.J.; Roth, E.M.; Taskinen, M.R.; Colhoun, H.M.; Brunet, A.; DiCioccio, A.T.; Lecorps, G.; Pordy, R.; Baccara-Dinet, M.T.; Cannon, C.P. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks. (September 2016) Authors: Farnier, M.; Colhoun, H.M.; Sasiela, W.J.; Edelberg, J.; Asset, G.; Robinson, J.G. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗